Clinical Report: Surgical Intervention Outcomes in Intrathoracic Pseudomyxoma Peritonei
Overview
This report evaluates the surgical outcomes of six patients with intrathoracic pseudomyxoma peritonei (PMP). The findings indicate that while surgical intervention can alleviate symptoms, long-term survival remains limited, with a 3-year survival rate of 33.3%.
Background
Intrathoracic metastasis from pseudomyxoma peritonei is rare and associated with poor prognosis. There are no established treatment guidelines, making management challenging for healthcare providers. Understanding surgical outcomes in this context is crucial for improving patient care and outcomes.
Data Highlights
Outcome
1-Year Survival Rate
3-Year Survival Rate
Overall
100% (6/6)
33.3% (2/6)
Key Findings
Six patients with intrathoracic PMP underwent surgical intervention from 2013 to 2022.
Five patients showed direct invasion into the pleural space.
Four patients had parietal/visceral pleurectomy to remove mucinous tissue.
One patient received lobectomy due to pulmonary metastases.
All patients experienced macroscopic tumor resection.
Average follow-up duration was 24 months.
Clinical Implications
Surgical intervention may provide symptomatic relief for patients with intrathoracic PMP, but the potential for long-term survival is limited. Clinicians should remain vigilant for perioperative complications and consider the overall prognosis when discussing treatment options with patients.
Conclusion
Intrathoracic pseudomyxoma peritonei presents significant treatment challenges, and while surgical approaches can alleviate symptoms, they do not guarantee improved long-term survival.
